Standard BioTools Inc

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Standard BioTools Inc posts strong Q4 results, targets margin improvement

Standard BioTools Inc delivered solid Q4 results with revenue growth and cost reductions. The outlook for 2023 includes flat to moderately higher core revenue, improved margins, and strategic expense management. Challenges in genomics and significant operating expenses require attention for sustained growth.

Standard BioTools Inc reports solid Q1 performance and eyes sustained growth

Standard BioTools Inc's Q1 2023 earnings call highlighted positive financial results, operational improvements, and strategic initiatives aimed at driving profitability. While facing challenges in certain revenue segments, the company's focus on cost reduction and revenue growth positions it well for future success.

Standard BioTools Inc. reports robust Q2 earnings, eyes growth opportunities

Standard BioTools Inc. delivered strong financial results in Q2 2023, with revenue growth and improved margins. The company's strategic priorities include stabilizing the core business, enhancing operating discipline, and leveraging M&A for growth. While challenges exist in managing profitability across segments, opportunities for growth through new products and strategic acquisitions are promising.

Standard BioTools Inc (LAB) reports strong Q3 earnings and advances merger with SomaLogic

Standard BioTools Inc (LAB) delivered robust financial results in Q3 2023, showcasing revenue growth, margin expansion, and operational improvements, setting a positive trajectory for future performance.
The company's strategic initiatives, including the pending merger with SomaLogic, signal a commitment to driving growth, fostering innovation, and enhancing shareholder value in a competitive market landscape.
While facing challenges in margin targets and post-merger integration, Standard BioTools Inc (LAB) remains well-positioned to capitalize on opportunities in biotechnology, expand market reach, and sustain its growth momentum.

Standard BioTools Inc (LAB) posts robust Q4 earnings and outlines growth strategies for 2024

Standard BioTools Inc (LAB) delivered a strong performance in Q4 2023, driven by revenue growth, margin expansion, and cost reduction.
The company's strategic focus on profitability, diversified revenue streams, and operational efficiency sets a solid foundation for future growth.
While facing challenges in cost synergies and margin maintenance, Standard BioTools Inc (LAB) is well-positioned to capitalize on opportunities for revenue growth and operational improvements.

Standard BioTools Inc achieves revenue growth and profitability in Q1

Standard BioTools Inc's Q1 2024 performance reflects steady revenue growth and improved profitability. The company's strategic initiatives and strong financial position with $464 million in cash equivalents provide a solid foundation for future growth and value creation.

Standard BioTools Inc accelerates cost reduction efforts amidst revenue challenges

Standard BioTools Inc's Q2 2024 performance focused on cost reduction, revised revenue guidance, and strategic partnerships for future growth.
The company aims to achieve breakeven adjusted EBITDA by 2026, supported by strong cash position and diversified revenue streams.
Challenges include contract delays in SomaScan services and suspension of share repurchase program, while opportunities lie in strategic M&A and new partnerships.
Overall, Standard BioTools Inc navigates market uncertainties with a focus on financial sustainability and operational efficiency for long-term success.

Standard BioTools Inc reports mixed Q3 results, focuses on growth

Standard BioTools Inc's Q3 performance reflects a mixed revenue picture with strong growth in Consumables but a decline in Instruments business. The company's focus on cost management and strategic initiatives to drive long-term growth and profitability is evident.
Maintaining a robust cash position and emphasizing high-margin consumables position Standard BioTools Inc well for future success. Addressing challenges in the Instruments segment and sustaining cost management are key priorities for the company moving forward.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that Ascendas Genomics has received approval from the National Medical Products Administration (NMPA) of China for use of the company's Biomark™ family of systems and its Juno™ system in NMPA molecular diagnostics services, enabling an important advance for microfluidics technology in the country.

Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China

The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needs The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needs

Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform

Standard BioTools Inc. (NASDAQ:LAB ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Peter DeNardo – Investor Relations Michael Egholm – Chief Executive Officer and President Vikram Jog – Chief Financial Officer Conference Call Participants Operator Hello, and welcome to the Standard BioTools Incorporated Second Quarter 2022 Financial Results Conference Call. As a reminder, this conference is being recorded.

Standard BioTools Inc. (LAB) CEO Michael Egholm on Q2 2022 Results - Earnings Call Transcript

Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update

Conduent

Ring Energy

Penny stocks to buy according to insiders. The post Best Penny Stocks To Buy In August According To Insiders, 1 Bet Over $2 Million appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy In August According To Insiders, 1 Bet Over $2 Million

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the market.

Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

CytoSorbents

ReWalk Robotics

Sunshine Biopharma

Troika Media Group

Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy In June According To These Insiders Part 1

Standard Bitola Inc. (NASDAQ:LAB ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Peter DeNardo – Investor Relations Michael Egholm – Chief Executive Officer and President Vikram Jog – Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to the Standard BioTools Inc. First Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Standard Bitola Inc. (LAB) CEO Michael Egholm on Q1 2022 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced financial results for the first quarter ended March 31, 2022.

Standard BioTools Announces First Quarter 2022 Financial Results

Atai Life Sciences BV

Limelight Networks

Retractable Technologies

Penny stocks to buy according to these insiders. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? Insiders Threw Big Money At These 4 Stocks

SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the market.

Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results

Capacity to Process 100-Plus Samples per Week, with 1.6x Lower Limit of Detection Capacity to Process 100-Plus Samples per Week, with 1.6x Lower Limit of Detection

Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging

Fluidigm

New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022

Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

News for Standard BioTools Inc Stock (LAB)